Vera Therapeutics : Submission of Matters to a Vote of Security Holders - Form 8-K
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ... | May 17, 2023
Source: marketscreener.com
📰 Patrickg Enright News
Patrickg Enright News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Patrickg Enright. Real-time updates on events, politics, business and more.
Molecular Templates : 10-K/A Filing FY 2022
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A ... | April 28, 2023
Source: marketscreener.com
Vera Therapeutics, Inc. (NASDAQ:VERA) Expected to Post Q1 2022 Earnings of ($0.67) Per Share
Vera Therapeutics, Inc. (NASDAQ:VERA – Get Rating) – Wedbush issued their Q1 2022 EPS estimates for Vera Therapeutics in a report issued on Monday, April 18th. Wedbush analyst L. Chico anticipates that the company will post earnings per share of ($0.67) for the quarter. Wedbush has a “Outperform” rating and a $32.00 price objective on […]
United States Patrickg Enright Securities Exchange Commission Vera Therapeutics Company Profile Get Rating Vera Therapeutics Inc Zacks Investment Research
Source: etfdailynews.com
Wedbush Initiates Coverage on Vera Therapeutics (NASDAQ:VERA)
Equities research analysts at Wedbush began coverage on shares of Vera Therapeutics (NASDAQ:VERA – Get Rating) in a report issued on Monday, The Fly reports. The brokerage set an “outperform” rating on the stock. VERA has been the topic of several other reports. Zacks Investment Research lowered Vera Therapeutics from a “hold” rating to a […]
United States Thomson Reuter Patrickg Enright Geode Capital Management Vera Therapeutics Company Profile Get Rating Vera Therapeutics Inc
Source: etfdailynews.com
Vera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick G. Enright Purchases 333,333 Shares
Vera Therapeutics, Inc. (NASDAQ:VERA – Get Rating) Director Patrick G. Enright acquired 333,333 shares of the business’s stock in a transaction dated Thursday, February 10th. The shares were purchased at an average price of $15.00 per share, with a total value of $4,999,995.00. The acquisition was disclosed in a legal filing with the SEC, which […]
United States Patrickg Enright Vera Therapeutics Company Profile Get Rating Vera Therapeutics Inc Zacks Investment Research Deutsche Bank
Source: etfdailynews.com